Aptar's Profitability Improving Due to Pharma Growth and Cost Controls
Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...
AirTAC Faces a Softer Demand Outlook Amid China’s Macroeconomic and Trade Uncertainties
We assign a Morningstar Uncertainty Rating of High to AirTAC, based on AirTAC’s fundamental exposure to the economy and economic cycles. More than 90% of AirTAC’s sales are generated from China in ...